10x Genomics, Inc. — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-04-01

Reporting Person: Hindson Benjamin J. (Director, See Remarks, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-01	Class A Common Stock	M	41666	$1.07	Acquired	78302	Direct
2021-04-01	Class A Common Stock	S	800	$179.9825	Disposed	77502	Direct
2021-04-01	Class A Common Stock	S	600	$181.50	Disposed	76902	Direct
2021-04-01	Class A Common Stock	S	1900	$182.4753	Disposed	75002	Direct
2021-04-01	Class A Common Stock	S	6686	$183.7438	Disposed	68316	Direct
2021-04-01	Class A Common Stock	S	16748	$184.5308	Disposed	51568	Direct
2021-04-01	Class A Common Stock	S	14632	$185.5223	Disposed	36936	Direct
2021-04-01	Class A Common Stock	S	300	$186.0783	Disposed	36636	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-01	Stock Option (right to buy)	$1.07	M	41666	Disposed	2026-11-18	Class A Common Stock (41666)	Direct

Footnotes

F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $179.80 to $180.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $180.96 to $181.91. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $181.96 to $182.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $183.02 to $184.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $184.02 to $185.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This transaction was executed in multiple trades at prices ranging from $185.02 to $185.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F8: This transaction was executed in multiple trades at prices ranging from $186.005 to $186.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F9: All of the shares subject to the option are fully vested and exercisable as of the date hereof.